LIPOSOMES WITH ENTRAPPED DOXORUBICIN EXHIBIT EXTENDED BLOOD RESIDENCE TIMES

被引:100
作者
BALLY, MB [1 ]
NAYAR, R [1 ]
MASIN, D [1 ]
HOPE, MJ [1 ]
CULLIS, PR [1 ]
MAYER, LD [1 ]
机构
[1] UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1W5, BC, CANADA
关键词
Blood residence time; chol; cholesterol; dipalmitoylphosphatidylcholine; distearoylphospatidylchone; Doxorubicin; DPPC; DSPC; egg PC; egg phospohatidylcholine; i.v; intravenous; large unilamellar vesicle; Liposome stability; LUV; MLV; multimellar vesicle; QELS; quasielastic light scattering; RES; reticuloendothelial system; small unilmellar vesicle; SUV;
D O I
10.1016/0005-2736(90)90018-J
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The blood residence time of liposomes with entrapped doxorubicin is shown to be significantly longer than for identically prepared empty liposomes. Liposomal doxorubin systems with a drug-to-lpid ratio of 0.2 (w/w) were administered at a dose of 100 mg lipid/kg. Both doxorubicin and liposomal lipid were quantified in order to assess in vivo stability and blood residence times. For empty vesicles composed of phosphatidylcholine (PC)/cholesterol (55:45, mole ratio) and sized through filters of 100 nm pore size, 15-25% of the administered lipid dose was recovered in the blood 24 h after i.v. injection. The percentage of the dose retained in the circulation at 24 h increased 2-3-fold when the liposomes contain entrapped doxorubicin. For 100 nm distearoyl PC/chol liposomal doxorubicin systems, as much as 80% of the injected dose of lipid and drug remain within the blood compartment 24 h after i.v. administration. © 1990.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 28 条
[1]   LIPOSOME UPTAKE BY HUMAN-LEUKOCYTES - ENHANCEMENT OF ENTRY MEDIATED BY HUMAN-SERUM AND AGGREGATED IMMUNOGLOBULINS [J].
FINKELSTEIN, MC ;
KUHN, SH ;
SCHIEREN, H ;
WEISSMANN, G ;
HOFFSTEIN, S .
BIOCHIMICA ET BIOPHYSICA ACTA, 1981, 673 (03) :286-302
[2]  
GABIZON A, 1982, CANCER RES, V42, P4734
[3]   LIPOSOME FORMULATIONS WITH PROLONGED CIRCULATION TIME IN BLOOD AND ENHANCED UPTAKE BY TUMORS [J].
GABIZON, A ;
PAPAHADJOPOULOS, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (18) :6949-6953
[4]  
HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8
[5]  
HUANG KJ, 1987, LIPOSOMES BIOPHYSICS, P109
[6]  
HUANG L, 1983, LIPOSOMES, P87
[8]   CLINICAL ANTICANCER PHARMACOLOGY - SOME PHARMACOKINETIC CONSIDERATIONS [J].
LEVIN, VA .
CANCER TREATMENT REVIEWS, 1986, 13 (02) :61-76
[9]   LIPOSOMAL AMPHOTERICIN-B FOR THE TREATMENT OF SYSTEMIC FUNGAL-INFECTIONS IN PATIENTS WITH CANCER - A PRELIMINARY-STUDY [J].
LOPEZBERESTEIN, G ;
FAINSTEIN, V ;
HOPFER, R ;
MEHTA, K ;
SULLIVAN, MP ;
KEATING, M ;
ROSENBLUM, MG ;
MEHTA, R ;
LUNA, M ;
HERSH, EM ;
REUBEN, J ;
JULIANO, RL ;
BODEY, GP .
JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (04) :704-710
[10]  
MAYER LD, 1989, CANCER RES, V49, P5922